DC Field | Value | Language |
dc.contributor.author | Lesnic, E. | |
dc.contributor.author | Ghinda, S. | |
dc.contributor.author | Rudic, V. | |
dc.date.accessioned | 2020-03-23T15:21:20Z | |
dc.date.available | 2020-03-23T15:21:20Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | LESNIC, E., GHINDA, S., RUDIC, V. Rolul activităţii immunocorectoare a remediului BioR la pacienţii cu eşec al tratamentului antituberculos. In: Curierul Medical. 2013, vol. 56, no 6, pp. 25-32. ISSN 1875-0666. | ro |
dc.identifier.issn | 1875-0666 | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/7840 | |
dc.identifier.uri | http://moldmedjournal.md/wp-content/uploads/2016/09/75.pdf | |
dc.description.abstract | Tuberculosis is a multi-pathogenetic disease, its treatment response is influenced by the degree immune disturbances. An acute progressive evolution
with extensive destruction and dissemination provokes the lowest treatment results, which in most cases are influenced by a heterogeneous immune
response. The immunological data obtained before and after the treatment of 54 new pulmonary TB cases have been compared with the data of 50 healthy
individuals. By a blind selection 27 TB patients have been included in the control study group and have been treated with the standard antituberculosis
treatment and immunocorrecting medicine BioR. The immune indices of 27 cases treated only with standard antituberculosis treatment have been
compared with the control group. The associated antituberculosis treatment have reduced the severity of the immune defficiency, reduced the increased
immune globulin level, increased the organism’s sensibilisation to bacteriological and micobacteriological antigens, reduced the intoxication indices. Despite
the immuno-regulatory activity of the medicine BioR, the comprehensive TB treatment in general has not improved the treatment results, as one course
of treatment is insufficient for a complete immune rehabilitation and the involvement of other factors, influencing the treatment outcomes is required. | en_US |
dc.language.iso | ro | en_US |
dc.publisher | Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” | en_US |
dc.subject | tuberculosis | en_US |
dc.subject | antituberculosis treatment failure | en_US |
dc.subject | immunity | en_US |
dc.subject.mesh | Tuberculosis, Pulmonary--drug therapy | en_US |
dc.subject.mesh | Tuberculosis, Pulmonary--immunology | en_US |
dc.subject.mesh | Treatment Failure | en_US |
dc.subject.mesh | BioR--therapeutic use | en_US |
dc.subject.mesh | Immunity, Cellular--drug effects | en_US |
dc.title | Rolul activităţii immunocorectoare a remediului BioR la pacienţii cu eşec al tratamentului antituberculos | ro |
dc.title.alternative | The role of the immunocorrective activity of the medicine BioR in the patients after a failed anti-tuberculosis treatment | en_US |
dc.type | Article | en_US |
Appears in Collections: | Curierul Medical, 2013, Vol. 56, Nr. 6
|